Tiger Pharmaceuticals (300347) In-depth Research Report: Local clinical CRO leaders are expected to fully benefit from the industry's rise in volume and price
TIGERMED(300347):MEANINGFUL DEMAND RECOVERY IN 1Q24
Tiger Pharmaceuticals (300347) Company Information Update Report: Performance is under phased pressure and is expected to gradually recover in 2024
Tiger Pharmaceuticals (300347): Short-term demand under pressure is expected to improve to drive a recovery in performance
Tiger Pharmaceuticals (300347): Multiple factors disrupt Q1 and expect innovative drug policies to boost the gradual recovery of the industry
Tiger Pharmaceuticals (300347): Business performance is basically in line with expectations, and innovation support policies are expected to reverse
Tiger Pharmaceuticals (300347): Optimistic about the inflection point driven by MRCT and MNC orders
Bank Rating | Lyon: Upgraded Tiger Pharmaceuticals and Zhaoyan New Drug Ratings Benefit from Innovative Drug Support Policies
Southwest Securities released a research report on April 8 stating that Tiger Pharmaceuticals (300347.SZ) was given a purchase rating. The main reasons for the rating include: 1) short-term profits were slightly disrupted, and the main business still show
Caixin Securities released a research report on April 8 stating that it gave Tiger Pharmaceuticals (300347.SZ) a purchase rating. The main reasons for the rating include: 1) incident: the company released its 2023 annual report; 2) the gross margin of cli
Tiger Pharmaceuticals (300347): Short-term profit fluctuations, overseas business continues to gain strength
Tiger Pharmaceuticals (300347): The impact of COVID-related businesses is gradually being clarified to accelerate the development of emerging businesses
Research Nuggets丨Cathay Pacific Junan: Tiger Pharmaceuticals' short-term profits have been disrupted in 23 years, and overseas business continues to expand
Tiger Pharmaceuticals (300347): Short-term profit disrupts overseas business continues to expand
Tiger Pharmaceuticals (300347): Clinical CRO leaders expect marginal changes in the innovative drug industry to bring about an improvement in prosperity
Tiger Pharmaceuticals (300347) Review: Short-term fluctuations in performance are expected to gradually recover in 24 years
Tiger Pharmaceuticals (300347): Short-term performance is under pressure, global layout is accelerating
Tiger Pharmaceuticals (300347): Revenue growth is steady, pending gradual fulfillment of ongoing orders
Tiger Pharmaceuticals (300347) 2023 Annual Report Review: Q1 Order Recovery Trend Is Good, Strengthening Overseas Business Expansion
Tiger Pharmaceuticals (300347): The global layout continues to deepen, and we look forward to the gradual improvement of operations in 2024
No Data